Novo Nordisk A/S disclosed headline Phase 3 data from the REDEFINE 4 trial showing that CagriSema, its fixed-dose combination of cagrilintide and semaglutide, achieved 23 percent weight loss over 84 weeks in people with obesity but failed to meet the primary endpoint of non-inferiority versus tirzepatide. The open-label head-to-head study compared once-weekly CagriSema 2.4 mg/2.4 […]
InventHelp’s heat therapy mitten targets hand pain, but what does it really change? Explore the evidence, regulatory gaps, and limits of consumer pain devices.
FDA approval expands Guerbet’s gadopiclenol into neonates, reinforcing half-dose MRI contrast strategies. Find out what this changes for pediatric imaging.
FDA approves milsaperidone for bipolar I disorder and schizophrenia. Explore what this means for psychiatry, competition, and Vanda Pharmaceuticals’ strategy.
